US20070015741A1 - Novel prodrugs of estradiol - Google Patents
Novel prodrugs of estradiol Download PDFInfo
- Publication number
- US20070015741A1 US20070015741A1 US11/478,584 US47858406A US2007015741A1 US 20070015741 A1 US20070015741 A1 US 20070015741A1 US 47858406 A US47858406 A US 47858406A US 2007015741 A1 US2007015741 A1 US 2007015741A1
- Authority
- US
- United States
- Prior art keywords
- estradiol
- prodrug
- compound
- pharmaceutically acceptable
- derivative
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- CASUHBNDRURTSO-GFEQUFNTSA-N [H][C@]12CC[C@]3(C)[C@@H](O)CC[C@@]3([H])[C@]1([H])CCC1=CC(C)=CC=C12 Chemical compound [H][C@]12CC[C@]3(C)[C@@H](O)CC[C@@]3([H])[C@]1([H])CCC1=CC(C)=CC=C12 CASUHBNDRURTSO-GFEQUFNTSA-N 0.000 description 5
- MGFKSUWDVZEAKU-INPNQFBTSA-N COC(=O)/C=C/C(=O)O.COC(=O)C(C)=O.COC(=O)C(C)O.COC(=O)C(C)OC(C)=O.COC(=O)CC1(CC(C)=O)OCOC1=O.COC(=O)CNC(=O)C[C@H](N)C(=O)O.COC(=O)COC(C)=O.COC(=O)C[C@H](O)C(=O)O.COC(=O)[C@@H](N)CC(=O)O.COC(=O)[C@@H](N)CO.COC(=O)[C@H](OC(C)=O)[C@H](OC(C)=O)C(=O)O.[H]N1CCC[C@H]1C(=O)OC Chemical compound COC(=O)/C=C/C(=O)O.COC(=O)C(C)=O.COC(=O)C(C)O.COC(=O)C(C)OC(C)=O.COC(=O)CC1(CC(C)=O)OCOC1=O.COC(=O)CNC(=O)C[C@H](N)C(=O)O.COC(=O)COC(C)=O.COC(=O)C[C@H](O)C(=O)O.COC(=O)[C@@H](N)CC(=O)O.COC(=O)[C@@H](N)CO.COC(=O)[C@H](OC(C)=O)[C@H](OC(C)=O)C(=O)O.[H]N1CCC[C@H]1C(=O)OC MGFKSUWDVZEAKU-INPNQFBTSA-N 0.000 description 4
- XAKITKDHDMPGPW-WDSKDSINSA-N CC(=O)O[C@@H]1C(=O)OC(=O)[C@H]1OC(C)=O Chemical compound CC(=O)O[C@@H]1C(=O)OC(=O)[C@H]1OC(C)=O XAKITKDHDMPGPW-WDSKDSINSA-N 0.000 description 2
- IDQOCLIWDMZKBZ-SCSAIBSYSA-N CC1(C)OC(=O)[C@@H](CC(=O)O)O1 Chemical compound CC1(C)OC(=O)[C@@H](CC(=O)O)O1 IDQOCLIWDMZKBZ-SCSAIBSYSA-N 0.000 description 2
- QTFFGYLLUHQSAS-UHFFFAOYSA-N COC(=O)C(C)OC(C)=O Chemical compound COC(=O)C(C)OC(C)=O QTFFGYLLUHQSAS-UHFFFAOYSA-N 0.000 description 2
- UKKSVRAQQBBJFY-HPCRKFCFSA-O B.CC(=O)C(=O)O.CC(=O)C(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.CC(O)C(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1C[CH+][C@@H]2O.[NaH] Chemical compound B.CC(=O)C(=O)O.CC(=O)C(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.CC(O)C(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1C[CH+][C@@H]2O.[NaH] UKKSVRAQQBBJFY-HPCRKFCFSA-O 0.000 description 1
- NFEODPYKZFFWMA-PSBCJMPLSA-M C1CCOC1.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(OC(=O)CC5(CC(=O)O)OCOC5=O)C=C4CCC3C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(OC(=O)CC5(CC(=O)O[Na])OCOC5=O)C=C4CCC3C1CC[C@@H]2O.O=C1CC2(CC(=O)O1)OCOC2=O Chemical compound C1CCOC1.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(OC(=O)CC5(CC(=O)O)OCOC5=O)C=C4CCC3C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(OC(=O)CC5(CC(=O)O[Na])OCOC5=O)C=C4CCC3C1CC[C@@H]2O.O=C1CC2(CC(=O)O1)OCOC2=O NFEODPYKZFFWMA-PSBCJMPLSA-M 0.000 description 1
- VKCOMBDXVRUQPK-UENPDLAXSA-N CC(=O)OCC(=O)O.CC(=O)OCC(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O Chemical compound CC(=O)OCC(=O)O.CC(=O)OCC(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O VKCOMBDXVRUQPK-UENPDLAXSA-N 0.000 description 1
- PMXNXKKYSRKHSI-QOFNLFPRSA-N CC(=O)O[C@@H](C)C(=O)O.CC(=O)O[C@@H](C)C(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O Chemical compound CC(=O)O[C@@H](C)C(=O)O.CC(=O)O[C@@H](C)C(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O PMXNXKKYSRKHSI-QOFNLFPRSA-N 0.000 description 1
- SGEPQEZNNOCVPQ-JBNRARDHSA-M CC(=O)O[C@@H]1C(=O)OC(=O)[C@H]1OC(C)=O.CC(=O)O[C@H](C(=O)O)[C@@H](OC(C)=O)C(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.CC(=O)O[C@H](C(=O)O[Na])[C@@H](OC(C)=O)C(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O Chemical compound CC(=O)O[C@@H]1C(=O)OC(=O)[C@H]1OC(C)=O.CC(=O)O[C@H](C(=O)O)[C@@H](OC(C)=O)C(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.CC(=O)O[C@H](C(=O)O[Na])[C@@H](OC(C)=O)C(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O SGEPQEZNNOCVPQ-JBNRARDHSA-M 0.000 description 1
- WAEWXZGXPMDHJT-IWELUARNSA-N CC(C)(C)OC(=O)N1CCC[C@@H]1C(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.CN1CCC[C@@H]1C(=O)O.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O.[2H]C#C.[H]N1CCC[C@@H]1C(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H]1C(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.CN1CCC[C@@H]1C(=O)O.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O.[2H]C#C.[H]N1CCC[C@@H]1C(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O WAEWXZGXPMDHJT-IWELUARNSA-N 0.000 description 1
- JCSIDWKXSPKDGY-ZCDOWHICSA-N CC(C)(C)OC(=O)NCC(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.CNC(CC(=O)NCC(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O)C(C)=O.CNCC(=O)O.CN[C@@H](CC(=O)O)C(C)=O.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(OC(=O)CN)C=C4CCC3C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(OC(=O)CNC(=O)CC(N)C(=O)O)C=C4CCC3C1CC[C@@H]2O.Cl.Cl Chemical compound CC(C)(C)OC(=O)NCC(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.CNC(CC(=O)NCC(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O)C(C)=O.CNCC(=O)O.CN[C@@H](CC(=O)O)C(C)=O.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(OC(=O)CN)C=C4CCC3C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(OC(=O)CNC(=O)CC(N)C(=O)O)C=C4CCC3C1CC[C@@H]2O.Cl.Cl JCSIDWKXSPKDGY-ZCDOWHICSA-N 0.000 description 1
- JWEFYMGRRVQKLV-BHVPLAMVSA-N CC(C)(C)OC(=O)N[C@H](CO)C(=O)O.CC(C)(C)OC(=O)N[C@H](CO)C(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(OC(=O)[C@H](N)CO)C=C4CCC3C1CC[C@@H]2O.Cl Chemical compound CC(C)(C)OC(=O)N[C@H](CO)C(=O)O.CC(C)(C)OC(=O)N[C@H](CO)C(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(OC(=O)[C@H](N)CO)C=C4CCC3C1CC[C@@H]2O.Cl JWEFYMGRRVQKLV-BHVPLAMVSA-N 0.000 description 1
- VDXODFCPYGXBQC-VRHQRQDJSA-N CC1(C)OC(=O)[C@@H](CC(=O)O)O1.CC1(C)OC(=O)[C@@H](CC(=O)OC2=CC=C3C(=C2)CCC2C3CC[C@@]3(C)C2CC[C@@H]3O)O1.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O Chemical compound CC1(C)OC(=O)[C@@H](CC(=O)O)O1.CC1(C)OC(=O)[C@@H](CC(=O)OC2=CC=C3C(=C2)CCC2C3CC[C@@]3(C)C2CC[C@@H]3O)O1.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O VDXODFCPYGXBQC-VRHQRQDJSA-N 0.000 description 1
- VHZKBRLDNKRFSQ-KWFSLBGQSA-N CC1(C)OC(=O)[C@@H](CC(=O)OC2=CC=C3C(=C2)CCC2C3CC[C@@]3(C)C2CC[C@@H]3O)O1.C[C@]12CCC3C4=CC=C(OC(=O)C[C@@H](O)C(=O)O)C=C4CCC3C1CC[C@@H]2O Chemical compound CC1(C)OC(=O)[C@@H](CC(=O)OC2=CC=C3C(=C2)CCC2C3CC[C@@]3(C)C2CC[C@@H]3O)O1.C[C@]12CCC3C4=CC=C(OC(=O)C[C@@H](O)C(=O)O)C=C4CCC3C1CC[C@@H]2O VHZKBRLDNKRFSQ-KWFSLBGQSA-N 0.000 description 1
- PPNXWODNFPBLCW-GPQDRKQFSA-N CN[C@@H](CC(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O)C(C)=O.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(OC(=O)C[C@H](N)C(=O)O)C=C4CCC3C1CC[C@@H]2O.Cl Chemical compound CN[C@@H](CC(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O)C(C)=O.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(OC(=O)C[C@H](N)C(=O)O)C=C4CCC3C1CC[C@@H]2O.Cl PPNXWODNFPBLCW-GPQDRKQFSA-N 0.000 description 1
- HUXRDNZVIJGQLI-RXMQYKEDSA-N CN[C@H](CC(=O)O)C(C)=O Chemical compound CN[C@H](CC(=O)O)C(C)=O HUXRDNZVIJGQLI-RXMQYKEDSA-N 0.000 description 1
- IKJJAZUBSBZFBX-JPYPVPHQSA-N CN[C@H](CC(C)=O)C(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(OC(=O)[C@H](N)CC(=O)O)C=C4CCC3C1CC[C@@H]2O.Cl Chemical compound CN[C@H](CC(C)=O)C(=O)OC1=CC=C2C(=C1)CCC1C2CC[C@@]2(C)C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(OC(=O)[C@H](N)CC(=O)O)C=C4CCC3C1CC[C@@H]2O.Cl IKJJAZUBSBZFBX-JPYPVPHQSA-N 0.000 description 1
- BNLMSTDLCLSGOS-HOPJCMJJSA-N C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(OC(=O)/C=C/C(=O)O)C=C4CCC3C1CC[C@@H]2O Chemical compound C[C@]12CCC3C4=CC=C(O)C=C4CCC3C1CC[C@@H]2O.C[C@]12CCC3C4=CC=C(OC(=O)/C=C/C(=O)O)C=C4CCC3C1CC[C@@H]2O BNLMSTDLCLSGOS-HOPJCMJJSA-N 0.000 description 1
- CKISKMVRUYIEFX-UHFFFAOYSA-N O=C1CC2(CC(=O)O1)OCOC2=O Chemical compound O=C1CC2(CC(=O)O1)OCOC2=O CKISKMVRUYIEFX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
- C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
Definitions
- This invention is directed to a prodrug derivative of estradiol and pharmaceutically acceptable salts thereof.
- the invention also includes pharmaceutical dosage units of the prodrug derivative.
- estradiol can be formulated as a conjugate, e.g., conjugated equine estrogens which are essentially estrogen metabolites purified from the urine of pregnant mares that contain sulfate and glucuronide derivatives (Martindale 32 ed , 1999, Pharmaceutical Press).
- estradiol esters are known in the art for oral administration of estrogen and include estradiol-3,17-diacetate, estradiol-17-acetate, estradiol-3,17-valerate, estradiol-3-valerate and estradiol-17-valerate. These esters rapidly hydrolyze to free estradiol following oral administration.
- U.S. Pat. No. 3,916,002 to Taubert et al. describes a number of oligomeric esters of androgenic, estrogenic and progestogenic steroids having the formula: R—O—CO—(CH 2 ) n —CO—O—R, wherein n is between 2 and 8, and each R is a monovalent steroid radical.
- the steroid radical is derived from steroids having a hydroxyl substituent at one of the carbon atoms numbered 3, 16 or 17. They can be produced by esterification of the two carboxyl radicals of a dicarboxylic acid with a steroid alcohol having a hydroxyl radical substituent at carbon atoms numbered 3, 16, or 17.
- the present invention is a prodrug derivative of estradiol according to Formula I: and enantiomers and pharmaceutically acceptable salts thereof, wherein X is selected from the group consisting of
- the present invention also includes a pharmaceutical dosage unit comprising (a) a prodrug of estradiol according to Formula I, and (b) one or more pharmaceutically acceptable excipients.
- a method of providing contraception comprises the step of administering to a patient in need thereof, an effective amount of a prodrug of estradiol of the invention, for an effective period of time.
- a method of providing hormone treatment therapy comprises the step of administering to a patient in need thereof, an effective amount of a prodrug of estradiol of the invention, for an effective period of time.
- a prodrug is an entity which either comprises an inactive form of an active drug or includes a chemical group which confers preferred characteristics on the drug.
- room temperature is understood to mean 25° C.+/ ⁇ 5° C.
- the prodrugs of estradiol have an X group attached to at the 3° C. position of an estradiol moiety.
- inventive compounds of Formula I include their enantiomers and their pharmaceutically acceptable salts.
- the prodrug of estradiol of the invention has the structural formula:
- X is selected from the group consisting of
- X is selected from the group consisting of:
- X attaches to the estradiol compound at the 3′C position of the estradiol compound.
- inventive compounds of Formula I include all their enantiomers and their pharmaceutically acceptable salts.
- pharmaceutically acceptable salt refers to a salt that retains the biological effectiveness of the free acids and bases of a specified compound and that is not biologically or otherwise undesirable.
- a pharmaceutical dosage unit may be formulated to include the prodrug derivative of estradiol of the present invention in combination with one or more pharmaceutically acceptable excipients.
- Excipients useful herein include a wide variety of additives, or ingredients, such as for example, fillers, diluents (solid and liquid), biocompatible polymers (such as organopolysiloxanes, polyurethanes and polymethylacrylates), skin penetrators and penetration enhancers, solubilizers, lubricants, stabilizers, flow control agents, colorants, glidants, effervescent agents, sweeteners, flavors, perfumes, and the like.
- additives such as for example, fillers, diluents (solid and liquid), biocompatible polymers (such as organopolysiloxanes, polyurethanes and polymethylacrylates), skin penetrators and penetration enhancers, solubilizers, lubricants, stabilizers, flow control agents, colorants, glidants, effervescent agents, sweeteners, flavors, perfumes, and the like.
- progestogens may be included in the pharmaceutical dosage unit.
- exemplary progestogens include norethindrone, drospirenone, trimegestone, levonorgestrel, desogestrel, 3-ketodesogestrel, gestodene, demegestone, dydrogesterone, medrogestone, medroxy progesterone and esters thereof and the like.
- the pharmaceutical dosage unit may be in an orally ingestible form, such as tablets, capsules, chewable tablets or capsules, troches, liquid suspensions, pills, or sustained release dosage forms.
- the pharmaceutical dosage unit may be a transdermal delivery system.
- the pharmaceutical dosage unit may be a topical composition such as a gel, cream, ointment, liquid and the like.
- the pharmaceutical dosage unit may be designed for vaginal administration e.g., a vaginal ring.
- estradiol may be synthesized using the methods described herein. These methods may be modified or alternative synthesis methods may be employed as desired. The synthesis methods typically begin with estradiol as the starting material. It should be understood, however, that where estradiol is indicated, derivatives of estradiol may be used.
- a fumaric acid estradiol ester may be formed in accordance to Reaction Sequence 1.
- the reaction combines estradiol and maleic anhydride in the presence of a base catalyst, e.g., sodium hexamethyldisilylamide (NaHMDS) and a solvent, e.g., tetrahydrofuran (THF) at ⁇ 78° C.
- a base catalyst e.g., sodium hexamethyldisilylamide (NaHMDS)
- a solvent e.g., tetrahydrofuran (THF)
- Deprotecting agents such as hydrochloric acid (HCl) and ether are then added to yield the desired product.
- Reaction Sequence 2 provides a route to synthesize a derivative estradiol ester compound by reacting estradiol or a derivative thereof with a compound having the structure in the presence of NaHMDS, maleic anhydride, and THF ( ⁇ 78° C.) to form an intermediate compound, which is then reacted with HCl/dioxane.
- a prodrug compound of the invention may be synthesized by reacting estradiol directly with a compound having a structure
- estradiol is reacted with pyruvic acid.
- An intermediate compound is formed, which is then treated with a deprotecting agent, such as sodium borohydride (NaBH 4 ).
- a deprotecting agent such as sodium borohydride (NaBH 4 ).
- NaBH 4 sodium borohydride
- an acetoxyacetic acid ester of estradiol is synthesized by reacting estradiol with acetoxyacetic acid.
- a prolinate estradiol ester derivative may be formed in accordance to Reaction Sequence 6. Estradiol is combined with Boc-proline in the presence of a coupling agent, e.g., DCC, forming an intermediate compound. A deprotecting agent, such as HCl/dioxane, is then added to form the desired prolinate estradiol ester derivative.
- a coupling agent e.g., DCC
- a deprotecting agent such as HCl/dioxane
- Reaction Sequence 7 provides a synthesis route for making a serine estradiol ester derivative.
- Estradiol is combined with Boc-serine.
- An intermediate compound is formed which is then reacted in the presence of a deprotecting agent, such as HCl/dioxane, to produce the serine estradiol ester.
- a deprotecting agent such as HCl/dioxane
- Reaction Sequence 8 provides a synthesis route for making the acetyl lactic acid ester derivative of estradiol, i.e., estradiol lactate-acetate. Estradiol is combined with acetyl lactic acid to form the desired compound.
- estradiol is combined with a compound having the structure to form an intermediate compound that is then treated with a deprotecting agent, such as HCl/ether, to yield diacetyltartaric acid estradiol ester.
- a deprotecting agent such as HCl/ether
- Reaction Sequence 10 depicts a process for synthesizing an Asp-Gly estradiol ester. Estradiol is combined with Boc-amino acetic acid, which forms an intermediate compound. As shown in Reaction Sequence 10, a compound having the structure is added to the intermediate compound, which is then treated with HCl to form the desired prodrug estradiol derivative ester.
- Reaction Sequence 11 starts by combining estradiol with Boc-aspartic acid t-butyl C 4 . This combination forms an intermediate compound, which is then treated with a deprotecting agent, such as HCl/dioxane to yield the aspartic acid estradiol ester.
- a deprotecting agent such as HCl/dioxane
- estradiol is reacted with Boc-aspartic acid t-butyl C 1 , which forms an intermediate compound.
- a deprotecting agent such as HCl/dioxane is combined with the intermediate compound to form the desired aspartic acid estradiol ester.
- estradiol As noted above, where estradiol is indicated, derivatives of estradiol may be used.
- Coupling agents that may be used in synthesizing the prodrug derivative of ethinyl estradiol of the present invention, may be for example, bis(4-nitrophenyl)carbonate (b-NPC), N,N′-dicyclohexyl-carbodiimide (DCC), 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (EDCI), and mixtures thereof.
- Alternative compounds may be used, so long as they fulfill the intended purpose.
- Deprotecting agents may be used in the synthesis reactions when needed.
- Non-limiting examples include HCl, dioxane, ether, sodium borohydride (NaBH 4 ), and mixtures thereof such as, for example, acetic acid:THF:water.
- a base may be used as a catalyst.
- Suitable bases include, but are not limited to DMAP, triethylamine, NaHMDS or mixtures thereof.
- Solvents that may be used in the synthesis reactions are for example, tetrahydrofuran (THF), chloroform, dichloromethane, and the like. However, it should be understood that many other organic solvents may be suitable.
- the prodrug may be treated to one or more washing steps, and/or recrystallization steps.
- the washing step may be used to rinse the precipitate that is formed by the prodrug of estradiol. As noted, one or more washing steps may be used. Water, sodium hydroxide, or any suitable alternative can be generally used for washing purposes.
- the purity may be increased by subjecting the prodrug to one or more recrystallization steps.
- the recrystallization step may be performed by various methods, and using suitable solvents such as but not limited to ethyl acetate, hexane or THF, or mixtures thereof.
- the drying step in the synthesis may be conducted by various methods including but not limited to, air drying, vacuum drying, oven drying, filtration, and the like. Drying may be enhanced by using a drying agent such as magnesium sulfate to assist in drying the product.
- a drying agent such as magnesium sulfate
- the prodrug of estradiol compounds of the present invention have been characterized using various analytical methods. For example, high performance liquid chromatography (HPLC) was used to establish the purity of the synthesized product. 1 H and 13 C nuclear magnetic resonance (NMR), mass spectrometry and infrared (IR) spectroscopy were used to verify its structure. Moreover, the product was further characterized by determining the melting point.
- HPLC high performance liquid chromatography
- NMR nuclear magnetic resonance
- IR infrared
- the prodrugs of the invention may be used for providing contraception.
- a therapeutically effective amount of the prodrug of estradiol of the invention is administered to a patient in need thereof, for an effective period of time.
- the prodrug is administered in combination with a progestogen.
- the prodrug of estradiol of the invention can also be used in providing hormone treatment therapy.
- Such a method of treatment would comprise the step of administering to a patient in need thereof, a therapeutically effective amount of a prodrug of estradiol of the invention, for an effective period of time.
- the prodrugs of estradiol of the present invention are administered in a “therapeutically effective amount.” This is understood to mean a sufficient amount of a compound or composition that will positively modify the symptoms and/or condition to be treated.
- the therapeutically effective amount can be readily determined by those of ordinary skill in the art, but of course will depend upon several factors. For example, one should consider the condition and severity of the condition being treated, the age, body weight, general health, diet, and physical condition of the patient being treated, the duration of the treatment, the nature of concurrent therapy, the particular active ingredient being employed, the particular pharmaceutically-acceptable excipients utilized, the time of administration, method of administration, rate of excretion, drug combination, and any other relevant factors.
- the prodrugs of the invention are preferably administered orally, transdermally, topically or vaginally.
- the preferred dosage forms are tablets, semi-solid dosage forms such as creams or gels, or vaginal rings.
- Stability was conducted at 40° C./75% RH, with the prodrug being assayed at specific time-points for degradation to the parent compound, estradiol.
- estradiol lactate acetate was assayed at 94.3% after storage at 3 months at 40° C./75% RH.
Abstract
Description
- This application claims the benefit of U.S. Provisional Application Ser. No. 60/698,866 filed on Jul. 12, 2005.
- 1. Field of the Invention
- This invention is directed to a prodrug derivative of estradiol and pharmaceutically acceptable salts thereof. The invention also includes pharmaceutical dosage units of the prodrug derivative.
- 2. Related Background Art
- Unbound 17β-estradiol is the most active, naturally occurring human estrogen. However, due to poor absorption and extensive first-pass metabolism in the gastrointestinal tract and liver following oral absorption, it is not generally orally active. Several methods have been utilized to increase its oral activity. A micronized form (to provide an increased surface area of drug for absorption) of estradiol which has sufficient oral bioavailability to be active is available. Alternatively estradiol can be formulated as a conjugate, e.g., conjugated equine estrogens which are essentially estrogen metabolites purified from the urine of pregnant mares that contain sulfate and glucuronide derivatives (Martindale 32ed, 1999, Pharmaceutical Press). These conjugates are orally active as they are hydrolyzed by enzymes in the lower gastrointestinal tract allowing absorption of the active estrogen. Another alternative is the oral administration of estradiol esters. Such compounds are known in the art for oral administration of estrogen and include estradiol-3,17-diacetate, estradiol-17-acetate, estradiol-3,17-valerate, estradiol-3-valerate and estradiol-17-valerate. These esters rapidly hydrolyze to free estradiol following oral administration.
- U.S. Pat. No. 3,916,002 to Taubert et al. describes a number of oligomeric esters of androgenic, estrogenic and progestogenic steroids having the formula: R—O—CO—(CH2)n—CO—O—R, wherein n is between 2 and 8, and each R is a monovalent steroid radical. The steroid radical is derived from steroids having a hydroxyl substituent at one of the carbon atoms numbered 3, 16 or 17. They can be produced by esterification of the two carboxyl radicals of a dicarboxylic acid with a steroid alcohol having a hydroxyl radical substituent at carbon atoms numbered 3, 16, or 17.
- A novel prodrug of estradiol that may increase oral activity would be highly advantageous.
-
- The present invention also includes a pharmaceutical dosage unit comprising (a) a prodrug of estradiol according to Formula I, and (b) one or more pharmaceutically acceptable excipients.
- In another aspect of the present invention, a method of providing contraception is provided. The method comprises the step of administering to a patient in need thereof, an effective amount of a prodrug of estradiol of the invention, for an effective period of time.
- In yet another aspect of the invention, a method of providing hormone treatment therapy is provided. The method comprises the step of administering to a patient in need thereof, an effective amount of a prodrug of estradiol of the invention, for an effective period of time.
- For the purposes of the present invention, a prodrug is an entity which either comprises an inactive form of an active drug or includes a chemical group which confers preferred characteristics on the drug.
- For the purposes of the present invention, room temperature is understood to mean 25° C.+/−5° C.
- In the present invention, the prodrugs of estradiol have an X group attached to at the 3° C. position of an estradiol moiety. It should be understood that the inventive compounds of Formula I include their enantiomers and their pharmaceutically acceptable salts.
-
-
-
- Notably, X attaches to the estradiol compound at the 3′C position of the estradiol compound. It should be understood that the inventive compounds of Formula I include all their enantiomers and their pharmaceutically acceptable salts.
- As used herein, the phrase “pharmaceutically acceptable salt” refers to a salt that retains the biological effectiveness of the free acids and bases of a specified compound and that is not biologically or otherwise undesirable.
- A pharmaceutical dosage unit may be formulated to include the prodrug derivative of estradiol of the present invention in combination with one or more pharmaceutically acceptable excipients.
- Excipients useful herein include a wide variety of additives, or ingredients, such as for example, fillers, diluents (solid and liquid), biocompatible polymers (such as organopolysiloxanes, polyurethanes and polymethylacrylates), skin penetrators and penetration enhancers, solubilizers, lubricants, stabilizers, flow control agents, colorants, glidants, effervescent agents, sweeteners, flavors, perfumes, and the like.
- Other steroids, e.g., progestogens may be included in the pharmaceutical dosage unit. Exemplary progestogens include norethindrone, drospirenone, trimegestone, levonorgestrel, desogestrel, 3-ketodesogestrel, gestodene, demegestone, dydrogesterone, medrogestone, medroxy progesterone and esters thereof and the like.
- The pharmaceutical dosage unit may be in an orally ingestible form, such as tablets, capsules, chewable tablets or capsules, troches, liquid suspensions, pills, or sustained release dosage forms. Alternatively, the pharmaceutical dosage unit may be a transdermal delivery system. Or in another embodiment the pharmaceutical dosage unit may be a topical composition such as a gel, cream, ointment, liquid and the like. Or in an alternative embodiment, the pharmaceutical dosage unit may be designed for vaginal administration e.g., a vaginal ring.
- The prodrug derivatives of estradiol may be synthesized using the methods described herein. These methods may be modified or alternative synthesis methods may be employed as desired. The synthesis methods typically begin with estradiol as the starting material. It should be understood, however, that where estradiol is indicated, derivatives of estradiol may be used.
- In one embodiment, a fumaric acid estradiol ester may be formed in accordance to Reaction Sequence 1. The reaction combines estradiol and maleic anhydride in the presence of a base catalyst, e.g., sodium hexamethyldisilylamide (NaHMDS) and a solvent, e.g., tetrahydrofuran (THF) at −78° C. Deprotecting agents such as hydrochloric acid (HCl) and ether are then added to yield the desired product.
- Reaction Sequence 2 provides a route to synthesize a derivative estradiol ester compound by reacting estradiol or a derivative thereof with a compound having the structure
in the presence of NaHMDS, maleic anhydride, and THF (−78° C.) to form an intermediate compound, which is then reacted with HCl/dioxane. -
-
-
-
- A prolinate estradiol ester derivative may be formed in accordance to Reaction Sequence 6. Estradiol is combined with Boc-proline in the presence of a coupling agent, e.g., DCC, forming an intermediate compound. A deprotecting agent, such as HCl/dioxane, is then added to form the desired prolinate estradiol ester derivative.
-
-
-
- Reaction Sequence 10 depicts a process for synthesizing an Asp-Gly estradiol ester. Estradiol is combined with Boc-amino acetic acid, which forms an intermediate compound. As shown in Reaction Sequence 10, a compound having the structure
is added to the intermediate compound, which is then treated with HCl to form the desired prodrug estradiol derivative ester. -
-
- As noted above, where estradiol is indicated, derivatives of estradiol may be used.
- Coupling agents that may be used in synthesizing the prodrug derivative of ethinyl estradiol of the present invention, may be for example, bis(4-nitrophenyl)carbonate (b-NPC), N,N′-dicyclohexyl-carbodiimide (DCC), 1-(3-dimethylaminopropyl)-3-ethyl-carbodiimide hydrochloride (EDCI), and mixtures thereof. Alternative compounds may be used, so long as they fulfill the intended purpose.
- Deprotecting agents may be used in the synthesis reactions when needed. Non-limiting examples include HCl, dioxane, ether, sodium borohydride (NaBH4), and mixtures thereof such as, for example, acetic acid:THF:water.
- In the synthesis reactions described, a base may be used as a catalyst. Suitable bases include, but are not limited to DMAP, triethylamine, NaHMDS or mixtures thereof.
- Solvents that may be used in the synthesis reactions are for example, tetrahydrofuran (THF), chloroform, dichloromethane, and the like. However, it should be understood that many other organic solvents may be suitable.
- To increase the purity of the prodrug of estradiol, the prodrug may be treated to one or more washing steps, and/or recrystallization steps.
- The washing step may be used to rinse the precipitate that is formed by the prodrug of estradiol. As noted, one or more washing steps may be used. Water, sodium hydroxide, or any suitable alternative can be generally used for washing purposes.
- As previously noted, the purity may be increased by subjecting the prodrug to one or more recrystallization steps. The recrystallization step may be performed by various methods, and using suitable solvents such as but not limited to ethyl acetate, hexane or THF, or mixtures thereof.
- The drying step in the synthesis may be conducted by various methods including but not limited to, air drying, vacuum drying, oven drying, filtration, and the like. Drying may be enhanced by using a drying agent such as magnesium sulfate to assist in drying the product.
- The prodrug of estradiol compounds of the present invention have been characterized using various analytical methods. For example, high performance liquid chromatography (HPLC) was used to establish the purity of the synthesized product. 1H and 13C nuclear magnetic resonance (NMR), mass spectrometry and infrared (IR) spectroscopy were used to verify its structure. Moreover, the product was further characterized by determining the melting point.
- The prodrugs of the invention may be used for providing contraception. A therapeutically effective amount of the prodrug of estradiol of the invention is administered to a patient in need thereof, for an effective period of time. Preferably, the prodrug is administered in combination with a progestogen.
- The prodrug of estradiol of the invention can also be used in providing hormone treatment therapy. Such a method of treatment would comprise the step of administering to a patient in need thereof, a therapeutically effective amount of a prodrug of estradiol of the invention, for an effective period of time.
- The prodrugs of estradiol of the present invention are administered in a “therapeutically effective amount.” This is understood to mean a sufficient amount of a compound or composition that will positively modify the symptoms and/or condition to be treated. The therapeutically effective amount can be readily determined by those of ordinary skill in the art, but of course will depend upon several factors. For example, one should consider the condition and severity of the condition being treated, the age, body weight, general health, diet, and physical condition of the patient being treated, the duration of the treatment, the nature of concurrent therapy, the particular active ingredient being employed, the particular pharmaceutically-acceptable excipients utilized, the time of administration, method of administration, rate of excretion, drug combination, and any other relevant factors.
- The prodrugs of the invention are preferably administered orally, transdermally, topically or vaginally. The preferred dosage forms are tablets, semi-solid dosage forms such as creams or gels, or vaginal rings.
- Specific embodiments of the invention will now be demonstrated by reference to the following examples. It should be understood that these examples are disclosed solely by way of illustrating the invention and should not be taken in any way to limit the scope of the present invention.
- The following is an example of stability for the preferred compound described previously. Stability was conducted at 40° C./75% RH, with the prodrug being assayed at specific time-points for degradation to the parent compound, estradiol. The time-points for stability were T=0 months, T=2 weeks, T=1 month, and T=3 months.
- The results of these studies on estradiol lactate-acetate, which may be prepared according to reaction sequence 8, are shown in TABLE 1.
TABLE 1 Assay (%) Prodrug Monomer T = 0 T = 2 W T = 1 T = 3 Estradiol Lactate-Acetate 94.45 93.47 92.77 94.3 - The following outlines the conditions utilized for analysis of the prodrug. Analysis was conducted using High-Performance Liquid Chromatography (HPLC). The retention time for estradiol lactate acetate was approximately 9.0 minutes using these conditions.
- Conditions for HPLC analysis:
Column: Symmetry Shield RP18 5 um, 4.6 × 250 mm Flow rate: 1.0 mL/min Temperature: Ambient Wavelength: 210 nm Injection Volume 10 μL Sample solvent: MeCN (acetonitrile) Retention Time: ˜9.0 minutes - As can be seen from TABLE 1, the estradiol lactate acetate was assayed at 94.3% after storage at 3 months at 40° C./75% RH.
- While the invention has been described above with reference to specific embodiments thereof, it is apparent that many changes, modifications, and variations can be made without departing from the inventive concept disclosed herein. Accordingly, it is intended to embrace all such changes, modifications, and variations that fall within the spirit and broad scope of the appended claims. All patent applications, patents, and other publications cited herein are incorporated by reference in their entirety.
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/478,584 US20070015741A1 (en) | 2005-07-12 | 2006-07-03 | Novel prodrugs of estradiol |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69886605P | 2005-07-12 | 2005-07-12 | |
US11/478,584 US20070015741A1 (en) | 2005-07-12 | 2006-07-03 | Novel prodrugs of estradiol |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070015741A1 true US20070015741A1 (en) | 2007-01-18 |
Family
ID=37488003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/478,584 Abandoned US20070015741A1 (en) | 2005-07-12 | 2006-07-03 | Novel prodrugs of estradiol |
Country Status (7)
Country | Link |
---|---|
US (1) | US20070015741A1 (en) |
EP (1) | EP1910402A2 (en) |
CN (1) | CN101228177A (en) |
CA (1) | CA2610481A1 (en) |
IL (1) | IL187633A0 (en) |
MX (1) | MX2008000412A (en) |
WO (1) | WO2007008474A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060292223A1 (en) * | 2005-06-16 | 2006-12-28 | Warner Chilcott Company Inc, | Gel compositions for topical administration |
US20070004694A1 (en) * | 2005-06-16 | 2007-01-04 | Warner Chilcott Company Inc. | Estrogen compositions for vaginal administration |
US20070004693A1 (en) * | 2005-06-16 | 2007-01-04 | Warner Chilcott Company Inc. | Estrogen compositions for vaginal administration |
WO2014152269A1 (en) | 2013-03-15 | 2014-09-25 | Warner Chilcott Company, Llc | Pharmaceutical soft gelatin capsule dosage form with modified guar gum |
WO2014152226A1 (en) | 2013-03-15 | 2014-09-25 | Warner Chilcott Company, Llc | Pharmaceutical soft gelatin capsule dosage form |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114933623B (en) * | 2022-04-26 | 2023-11-03 | 深圳市妇幼保健院 | Estradiol derivative and preparation method and application thereof |
Citations (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2205627A (en) * | 1936-07-30 | 1940-06-25 | Chem Ind Basel | Esters of unsaturated polyhydroxy estrane |
US2840508A (en) * | 1951-05-17 | 1958-06-24 | Schering Ag | Injectable steroid hormone preparations and method of making same |
US3766223A (en) * | 1971-04-06 | 1973-10-16 | Warner Lambert Co | Disteroidyl ethers |
US3828081A (en) * | 1971-03-30 | 1974-08-06 | Warner Lambert Co | Steroidyl-estratrienes |
US3916002A (en) * | 1973-12-17 | 1975-10-28 | Taubert Hans Dieter | Oligomeric steroid esters, process for their production, and therapeutic compositions containing the same |
US3952030A (en) * | 1972-12-27 | 1976-04-20 | The Radiochemical Centre Ltd. | Selenium-75 steroids |
US3989828A (en) * | 1973-08-09 | 1976-11-02 | Robert Aries | Mixed esters of estradiol and zeranol |
US4002747A (en) * | 1974-12-02 | 1977-01-11 | Akzona Incorporated | Novel ester of 19-nor-testosterone |
US4198405A (en) * | 1978-01-31 | 1980-04-15 | Kureha Kagaku Kogyo Kabushiki Kaisha | Prostaglandine derivatives |
US4310511A (en) * | 1980-10-02 | 1982-01-12 | Massachusetts General Hospital | Sunscreen compositions containing Δ5,7 steroidal dienes |
US4774236A (en) * | 1986-09-17 | 1988-09-27 | Research Triangle Institute | 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them |
US4948593A (en) * | 1989-05-15 | 1990-08-14 | Alza Corporation | Osmotic dosage form comprising an estrogen and a progestogen |
US5116828A (en) * | 1989-10-26 | 1992-05-26 | Nippon Zoki Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of osteoporosis |
US5117015A (en) * | 1988-07-04 | 1992-05-26 | Teijin Limited | Process for production of 1-α, 3-β, 24-trihydroxy Δ-5 |
US5610149A (en) * | 1995-05-12 | 1997-03-11 | The Research Foundation Of State University Of New York | Steroidal polyamines |
US5760214A (en) * | 1993-03-25 | 1998-06-02 | Iskra Industry Co., Ltd. | Bone resorption inhibition/osteogenesis promotion compound |
US5888996A (en) * | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
US5955068A (en) * | 1997-04-14 | 1999-09-21 | Universite De Montreal | Biodegradable polanhydrides derived from dimers of bile acids, and use thereof as controlled drug release systems |
US5989581A (en) * | 1997-04-11 | 1999-11-23 | Akzo Nobel N.V. | Drug delivery system for two or more active substances |
US6083941A (en) * | 1995-07-24 | 2000-07-04 | Trustees Of Boston University | Inhibition of NMDA receptor activity by pregnenolone sulfate derivatives |
US6375930B2 (en) * | 1996-06-04 | 2002-04-23 | Board Of Regents, The University Of Texas System | Membrane incorporation of texaphyrins |
US6441206B1 (en) * | 1997-09-09 | 2002-08-27 | Raisio Benecol Ltd. | Use of organic acid esters in dietary fat |
US20020131991A1 (en) * | 1997-12-16 | 2002-09-19 | Norman Milstein | Processes for preparing sterol esters |
US20030077297A1 (en) * | 1999-02-26 | 2003-04-24 | Feng-Jing Chen | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US20050159399A1 (en) * | 2004-01-15 | 2005-07-21 | Galen (Chemicals) Limited | Di-steroidal prodrugs of estradiol |
US20050159609A1 (en) * | 2004-01-15 | 2005-07-21 | Galen (Chemicals) Limited | Di-steroidal prodrugs of ethinyl estradiol |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB833582A (en) * | 1956-08-14 | 1960-04-27 | Organon Labor Ltd | New steroid esters and the preparation thereof |
-
2006
- 2006-07-03 EP EP06786141A patent/EP1910402A2/en not_active Withdrawn
- 2006-07-03 US US11/478,584 patent/US20070015741A1/en not_active Abandoned
- 2006-07-03 CA CA002610481A patent/CA2610481A1/en not_active Abandoned
- 2006-07-03 MX MX2008000412A patent/MX2008000412A/en not_active Application Discontinuation
- 2006-07-03 CN CNA2006800247258A patent/CN101228177A/en active Pending
- 2006-07-03 WO PCT/US2006/025853 patent/WO2007008474A2/en active Application Filing
-
2007
- 2007-11-26 IL IL187633A patent/IL187633A0/en unknown
Patent Citations (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2205627A (en) * | 1936-07-30 | 1940-06-25 | Chem Ind Basel | Esters of unsaturated polyhydroxy estrane |
US2840508A (en) * | 1951-05-17 | 1958-06-24 | Schering Ag | Injectable steroid hormone preparations and method of making same |
US3828081A (en) * | 1971-03-30 | 1974-08-06 | Warner Lambert Co | Steroidyl-estratrienes |
US3766223A (en) * | 1971-04-06 | 1973-10-16 | Warner Lambert Co | Disteroidyl ethers |
US3952030A (en) * | 1972-12-27 | 1976-04-20 | The Radiochemical Centre Ltd. | Selenium-75 steroids |
US3989828A (en) * | 1973-08-09 | 1976-11-02 | Robert Aries | Mixed esters of estradiol and zeranol |
US3916002A (en) * | 1973-12-17 | 1975-10-28 | Taubert Hans Dieter | Oligomeric steroid esters, process for their production, and therapeutic compositions containing the same |
US4002747A (en) * | 1974-12-02 | 1977-01-11 | Akzona Incorporated | Novel ester of 19-nor-testosterone |
US4198405A (en) * | 1978-01-31 | 1980-04-15 | Kureha Kagaku Kogyo Kabushiki Kaisha | Prostaglandine derivatives |
US4310511A (en) * | 1980-10-02 | 1982-01-12 | Massachusetts General Hospital | Sunscreen compositions containing Δ5,7 steroidal dienes |
US4774236A (en) * | 1986-09-17 | 1988-09-27 | Research Triangle Institute | 17α-(substituted-methyl)-17β-hydroxy/esterified hydroxy steroids and pharmaceutical compositions containing them |
US5117015A (en) * | 1988-07-04 | 1992-05-26 | Teijin Limited | Process for production of 1-α, 3-β, 24-trihydroxy Δ-5 |
US4948593A (en) * | 1989-05-15 | 1990-08-14 | Alza Corporation | Osmotic dosage form comprising an estrogen and a progestogen |
US5116828A (en) * | 1989-10-26 | 1992-05-26 | Nippon Zoki Pharmaceutical Co., Ltd. | Pharmaceutical composition for treatment of osteoporosis |
US5760214A (en) * | 1993-03-25 | 1998-06-02 | Iskra Industry Co., Ltd. | Bone resorption inhibition/osteogenesis promotion compound |
US6028207A (en) * | 1993-03-25 | 2000-02-22 | Iskra Industry Co., Ltd. | Bone resorption inhibition/osteogenesis promotion compound |
US5610149A (en) * | 1995-05-12 | 1997-03-11 | The Research Foundation Of State University Of New York | Steroidal polyamines |
US6083941A (en) * | 1995-07-24 | 2000-07-04 | Trustees Of Boston University | Inhibition of NMDA receptor activity by pregnenolone sulfate derivatives |
US5888996A (en) * | 1995-07-26 | 1999-03-30 | Trustees Of Boston University | Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity |
US6375930B2 (en) * | 1996-06-04 | 2002-04-23 | Board Of Regents, The University Of Texas System | Membrane incorporation of texaphyrins |
US5989581A (en) * | 1997-04-11 | 1999-11-23 | Akzo Nobel N.V. | Drug delivery system for two or more active substances |
US5955068A (en) * | 1997-04-14 | 1999-09-21 | Universite De Montreal | Biodegradable polanhydrides derived from dimers of bile acids, and use thereof as controlled drug release systems |
US6441206B1 (en) * | 1997-09-09 | 2002-08-27 | Raisio Benecol Ltd. | Use of organic acid esters in dietary fat |
US20020131991A1 (en) * | 1997-12-16 | 2002-09-19 | Norman Milstein | Processes for preparing sterol esters |
US20030077297A1 (en) * | 1999-02-26 | 2003-04-24 | Feng-Jing Chen | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US20050159399A1 (en) * | 2004-01-15 | 2005-07-21 | Galen (Chemicals) Limited | Di-steroidal prodrugs of estradiol |
US20050159609A1 (en) * | 2004-01-15 | 2005-07-21 | Galen (Chemicals) Limited | Di-steroidal prodrugs of ethinyl estradiol |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060292223A1 (en) * | 2005-06-16 | 2006-12-28 | Warner Chilcott Company Inc, | Gel compositions for topical administration |
US20070004694A1 (en) * | 2005-06-16 | 2007-01-04 | Warner Chilcott Company Inc. | Estrogen compositions for vaginal administration |
US20070004693A1 (en) * | 2005-06-16 | 2007-01-04 | Warner Chilcott Company Inc. | Estrogen compositions for vaginal administration |
US10016442B2 (en) | 2005-06-16 | 2018-07-10 | Allergan Pharmaceuticals International Limited | Estrogen compositions for vaginal administration |
WO2014152269A1 (en) | 2013-03-15 | 2014-09-25 | Warner Chilcott Company, Llc | Pharmaceutical soft gelatin capsule dosage form with modified guar gum |
WO2014152226A1 (en) | 2013-03-15 | 2014-09-25 | Warner Chilcott Company, Llc | Pharmaceutical soft gelatin capsule dosage form |
EP3187170A1 (en) | 2013-03-15 | 2017-07-05 | Warner Chilcott Company, LLC | Pharmaceutical soft gelatin capsule dosage form with modified guar gum |
US9795569B2 (en) | 2013-03-15 | 2017-10-24 | Allergan Pharmaceuticals International Limited | Pharmaceutical soft gelatin capsule dosage form with modified guar gum |
US9820946B2 (en) | 2013-03-15 | 2017-11-21 | Allergan Pharmaceuticals International Limited | Pharmaceutical soft gelatin capsule dosage form with modified guar gum |
US10744096B2 (en) | 2013-03-15 | 2020-08-18 | Allergan Pharmaceuticals International Limited | Pharmaceutical soft gelatin capsule dosage form with modified guar gum |
Also Published As
Publication number | Publication date |
---|---|
MX2008000412A (en) | 2008-03-10 |
EP1910402A2 (en) | 2008-04-16 |
CN101228177A (en) | 2008-07-23 |
CA2610481A1 (en) | 2007-01-18 |
WO2007008474A3 (en) | 2007-08-30 |
IL187633A0 (en) | 2008-03-20 |
WO2007008474A2 (en) | 2007-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7795241B2 (en) | Derivative prodrugs of ethinyl estradiol | |
US8853190B2 (en) | Steroids having increased water solubility and resistance against metabolism, and methods for their production | |
JP4368945B2 (en) | Novel 19-noroop legnene derivatives | |
US20070015741A1 (en) | Novel prodrugs of estradiol | |
CA2274779A1 (en) | Aminosterol ester compounds | |
KR100744701B1 (en) | Steroid nitrates for the treatment of oxidative injury and endothelial dysfunction | |
JP2003530403A (en) | 8β-substituted 11β-pentyl- and 11β-hexyl-estra-1,3,5 (10) -triene derivatives | |
JPH07149789A (en) | New 11-benzaldoxime-estradiene derivative, its production and medicinal preparation containing this compound | |
US7067505B2 (en) | Di-steroidal prodrugs of estradiol | |
JPH07149790A (en) | New 11-benzaldoxime-17 beta-methoxy-17 alpha-methoxymethyl-estradiene derivative, its preparation and medicinal preparation containing this substance | |
US7067504B2 (en) | Di-steroidal prodrugs of ethinyl estradiol | |
EP0412907A2 (en) | New organic acid esters of alcoholic derivatives of 19-nor steroids and their salts, process for their preparation and intermediates thereof, their use as medicines and pharmaceutical compositions containing them | |
US6514956B1 (en) | Steroids, their preparation, pharmaceutical compositions thereof and uses of the compounds | |
TW200911824A (en) | 8-beta-substituted estratrienes as selectively active estrogens | |
US6579864B1 (en) | 3-methylene steroid derivatives | |
JP2007532688A (en) | 17α-Fluoro-17β-hydroxyiminomethyl steroids, processes for preparing them and pharmaceutical compositions comprising said compounds | |
JPS6363698A (en) | Bile acid derivative, salt and production thereof | |
JPS63255296A (en) | Estradiol derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: WARNER CHILCOTT COMPANY, INC., PUERTO RICO Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KEOWN, JAMES;MCILROY, JAMES WILLIAM;KING, JOHN ALEXANDER;AND OTHERS;REEL/FRAME:018316/0779 Effective date: 20060822 |
|
AS | Assignment |
Owner name: WARNER CHILCOTT COMPANY, LLC, PUERTO RICO Free format text: CHANGE OF NAME;ASSIGNOR:WARNER CHILCOTT COMPANY, INC.;REEL/FRAME:022835/0896 Effective date: 20090413 Owner name: WARNER CHILCOTT COMPANY, LLC,PUERTO RICO Free format text: CHANGE OF NAME;ASSIGNOR:WARNER CHILCOTT COMPANY, INC.;REEL/FRAME:022835/0896 Effective date: 20090413 |
|
AS | Assignment |
Owner name: CREDIT SUISSE, CAYMAN ISLANDS BRANCH, AS ADMINISTR Free format text: SECURITY AGREEMENT;ASSIGNOR:WARNER CHILCOTT COMPANY, LLC;REEL/FRAME:023456/0052 Effective date: 20091030 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: WARNER CHILCOTT COMPANY LLC, PUERTO RICO Free format text: RELEASE - REEL 023456, FRAME 0052;ASSIGNOR:CREDIT SUISSSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT;REEL/FRAME:026042/0046 Effective date: 20110317 |